SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2370-2376

  Mayer, E L ^a   Dhakil, S ^b   Patel, T ^c   Sundaram, S ^d   Fabian, C ^e   Kozloff, M ^f   Qamar, R ^g   Volterra, F ^h   Parmar, H ⁱ   Samant, M ⁱ   Burstein, H J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Cancer Center of Kansas   (United States)

^c Mark H Zangmeister Center   (United States)

^d SHARP HEALTHCARE   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f Ingalls Memorial Hospital   (United States)

^g Glendale WI   (United States)

^h Eastchester Cancer Care ^*  (United States)

ⁱ GENENTECH INC   (United States)

Author keywords

Antiangiogenesis; Bevacizumab; Breast cancer; Combination biologics; Sunitinib; VEGF

Indexed keywords

BEVACIZUMAB; PACLITAXEL; SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PACLITAXEL; PYRROLES; TREATMENT OUTCOME;

EID: 77957604275     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq260     Document Type: Article

References (23)

1. Gasparini G. Angiogenesis in breast cancer: role in biology, tumor progression, and prognosis. In Bowcock A (ed): Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics. Totowa, NJ: Humana Press 1999; 347-371.
2. Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002; 29 (3 Suppl 11): 104-110.
3. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as firstline therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26(15S): LBA1011.
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.
5. Robert N, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27 (15S): A1005.
6. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-2049.
7. Ebos JM, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007; 104(43): 17069-17074.
8. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26(11): 1810-1816.
9. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8(8): 579-591.
10. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007; 13(2 Pt 2): 764s-769s.
11. Feldman D, Kondagunta G, Ronnen E, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007; 25(18S): A5099.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
13. Feldman D, Ginsberg M, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26(15S): A5100.
14. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(9): 1432-1439.
15. Cooney M, Garcia J, Elson P, et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. J Clin Oncol 2008; 26: A3530.
16. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26(22): 3709-3714.
17. Sosman J, Flaherty K, Atkins M, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008; 26(15S): A5011.
18. Genentech, Inc.; South San Francisco, CA, 2009.
19. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008; 26(22): 3665-3667.
20. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8): 1227-1234.
21. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26(28): 4672-4678.
22. Rini B, Schiller J, Fruehauf J, et al. Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 2008; 26(15S): A3543.
23. O'Shaughnessy J, Blackwell K, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008; 26(15S): A1015.